Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2004 1
2005 2
2006 1
2007 2
2008 2
2009 1
2010 1
2011 1
2012 3
2013 1
2014 2
2015 1
2017 2
2018 3
2019 1
2022 1
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

20 results

Results by year

Filters applied: . Clear all
Page 1
Mechanism of receptor assembly via the pleiotropic adipokine Leptin.
Tsirigotaki A, Dansercoer A, Verschueren KHG, Marković I, Pollmann C, Hafer M, Felix J, Birck C, Van Putte W, Catteeuw D, Tavernier J, Fernando Bazan J, Piehler J, Savvides SN, Verstraete K. Tsirigotaki A, et al. Among authors: catteeuw d. Nat Struct Mol Biol. 2023 Apr;30(4):551-563. doi: 10.1038/s41594-023-00941-9. Epub 2023 Mar 23. Nat Struct Mol Biol. 2023. PMID: 36959263
A bispecific Clec9A-PD-L1 targeted type I interferon profoundly reshapes the tumor microenvironment towards an antitumor state.
Van Lint S, Van Parys A, Van Den Eeckhout B, Vandamme N, Plaisance S, Verhee A, Catteeuw D, Rogge E, De Geest J, Vanderroost N, Roels J, Saeys Y, Uzé G, Kley N, Cauwels A, Tavernier J. Van Lint S, et al. Among authors: catteeuw d. Mol Cancer. 2023 Nov 29;22(1):191. doi: 10.1186/s12943-023-01908-6. Mol Cancer. 2023. PMID: 38031106 Free PMC article.
Delivering Type I Interferon to Dendritic Cells Empowers Tumor Eradication and Immune Combination Treatments.
Cauwels A, Van Lint S, Paul F, Garcin G, De Koker S, Van Parys A, Wueest T, Gerlo S, Van der Heyden J, Bordat Y, Catteeuw D, Rogge E, Verhee A, Vandekerckhove B, Kley N, Uzé G, Tavernier J. Cauwels A, et al. Among authors: catteeuw d. Cancer Res. 2018 Jan 15;78(2):463-474. doi: 10.1158/0008-5472.CAN-17-1980. Epub 2017 Nov 29. Cancer Res. 2018. PMID: 29187401
Elongin B/C recruitment regulates substrate binding by CIS.
Piessevaux J, De Ceuninck L, Catteeuw D, Peelman F, Tavernier J. Piessevaux J, et al. Among authors: catteeuw d. J Biol Chem. 2008 Aug 1;283(31):21334-46. doi: 10.1074/jbc.M803742200. Epub 2008 May 28. J Biol Chem. 2008. PMID: 18508766 Free article.
A safe and highly efficient tumor-targeted type I interferon immunotherapy depends on the tumor microenvironment.
Cauwels A, Van Lint S, Garcin G, Bultinck J, Paul F, Gerlo S, Van der Heyden J, Bordat Y, Catteeuw D, De Cauwer L, Rogge E, Verhee A, Uzé G, Tavernier J. Cauwels A, et al. Among authors: catteeuw d. Oncoimmunology. 2017 Nov 27;7(3):e1398876. doi: 10.1080/2162402X.2017.1398876. eCollection 2018. Oncoimmunology. 2017. PMID: 29399401 Free PMC article.
Leptin's metabolic and immune functions can be uncoupled at the ligand/receptor interaction level.
Zabeau L, Jensen CJ, Seeuws S, Venken K, Verhee A, Catteeuw D, van Loo G, Chen H, Walder K, Hollis J, Foote S, Morris MJ, Van der Heyden J, Peelman F, Oldfield BJ, Rubio JP, Elewaut D, Tavernier J. Zabeau L, et al. Among authors: catteeuw d. Cell Mol Life Sci. 2015 Feb;72(3):629-644. doi: 10.1007/s00018-014-1697-x. Epub 2014 Aug 7. Cell Mol Life Sci. 2015. PMID: 25098352 Free PMC article.
20 results